Entering text into the input field will update the search result below

Acer Therapeutics stock down after FDA declines to approve urea cycle disorders treatment

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug, ACER-001, to treat patients with urea cycle disorders, rare genetic conditions primarily diagnosed

Recommended For You

Related Stocks

SymbolLast Price% Chg
ACER
--
RLFTF
--